SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: SG who wrote (571)3/3/1998 12:44:00 AM
From: FNS  Read Replies (1) | Respond to of 965
 
SG: << why is the market trashing it? It appears to work...>> Agree, but not a 100% sure thing that the FDA will approve it soon (???) and if so, by what date?

Further, Holveck has said a partnership is still being pursued...but not having been updated, shareholders can get mighty impatient! It would be nice to hear some positive news at the bio meeting in CA on March 15th.

FNS



To: SG who wrote (571)3/9/1998 9:33:00 PM
From: Wilfredo Pagani  Read Replies (3) | Respond to of 965
 
Avakine seems to require more time to be used at office levels . Its appear to require intravenous infussion for two hours , not clear about dose and how many times it had to be given in a year. It seems to be reserved for the research hospitals for getting more information. No evidence to suggest that it will be used in all Crohns patients , probably only in those that failed to usual therapy. Little concern with medicolegal trouble. WPagani


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News